Milestone Scientific Inc. Completes $2.15 Million Private Placement

Rhea-AI Summary

Milestone Scientific (NYSE:MLSS) closed a $2.15 million private placement of common stock and warrants on April 20, 2026, with an additional $2.69 million available if cash warrants are fully exercised. The company sold 7,962,963 units at $0.27 per unit; each unit includes one share and one warrant exercisable at 125% of the unit price.

Proceeds comprised approximately $1.80 million cash and $351,000 from conversion of 2025 convertible bridge notes. Directors and officers, including the CEO and chairman, participated for an aggregate $150,000 cash purchase. The placement closed April 20, 2026, under NYSE American rules.

Positive

• $2.15M raised to strengthen balance sheet
• Directors and officers invested $150K, signaling board confidence
• Units priced at $0.27 with warrants exercisable at 125%, offering upside

Negative

• Issuance of 7,962,963 new units will dilute existing shareholders
• Only $1.80M of the $2.15M was cash; $351K came from note conversions
• Additional funding of $2.69M depends on future warrant exercises (contingent)

News Market Reaction – MLSS

+8.69%

18 alerts

+8.69% News Effect

+23.0% Peak Tracked

-2.6% Trough Tracked

+$2M Valuation Impact

$27.09M Market Cap

0.5x Rel. Volume

On the day this news was published, MLSS gained 8.69%, reflecting a notable positive market reaction. Argus tracked a peak move of +23.0% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $27.09M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement size: $2.15 million Additional warrant proceeds: $2.69 million Units issued: 7,962,963 units +5 more

8 metrics

Private placement size $2.15 million Common stock and warrants offering closed April 20, 2026

Additional warrant proceeds $2.69 million If all cash warrants from private placement are fully exercised

Units issued 7,962,963 units Private placement of common stock and warrants at $0.27 per unit

Unit price $0.27 per unit Price per unit in April 20, 2026 private placement

Warrant strike level 125% of unit price Cash warrant exercise price set as percentage of unit purchase price

Cash raised $1.80 million Cash portion of the $2.15 million private placement

Debt conversion $351,000 Conversion of convertible bridge notes issued to certain directors

Insider cash participation $150,000 Directors and officers’ cash investment in the private placement units

Market Reality Check

Price: $0.3240 Vol: Volume 1,724,825 is about...

low vol

$0.3240 Last Close

Volume Volume 1,724,825 is about 70% below the 20-day average of 5,659,929 (relative volume 0.3x). low

Technical Price at $0.29, trading below the 200-day MA of $0.41 and 73.87% under the 52-week high.

Peers on Argus

Argus momentum data flags a broader move with 3 peers moving down (median around...

1 Up 3 Down

Argus momentum data flags a broader move with 3 peers moving down (median around -3.6%) and 1 moving up. Scanner peers like FEMY, EKSO and HBIO are down, while NXGL is up, suggesting mixed but generally negative sector pressure around Medical Instruments & Supplies.

Historical Context

5 past events · Latest: Mar 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 31	Full-year earnings	Positive	+3.7%	2025 results and 2026 growth outlook with improving operating loss profile.
Mar 26	Earnings call schedule	Neutral	-6.8%	Announcement of timing and access details for FY 2025 results call.
Feb 23	Commercial program launch	Positive	+0.1%	Launch of CompuFlo Advisor Program to boost adoption and reimbursement data.
Jan 06	Dental program launch	Negative	-4.3%	Update highlighting stable revenue but continued losses and transformation efforts.
Nov 13	Q3 2025 results	Negative	-13.1%	Q3 2025 results with modest revenue, operating loss and going concern pressure.

Pattern Detected

News flow has focused on restructuring-to-growth, new commercial programs, and recurring losses, with mixed price reactions—some operating updates saw declines while the latest full-year results were followed by a modest gain.

Recent Company History

Over the last six months, Milestone Scientific has reported sequential operating improvements and commercial initiatives alongside ongoing losses. Q3 2025 results on Nov 13, 2025 showed reduced operating loss but triggered a -13.09% move. Programs like The Wand Ambassador launch and CompuFlo Advisor aimed to drive adoption and utilization with muted price impact. The 2025 results and 2026 outlook released on Mar 31, 2026 brought revenue of $9.0M and an improved operating loss of $5.7M, with shares up 3.68% the next day.

Market Pulse Summary

The stock moved +8.7% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.7% in the session following this news. A strong positive reaction aligns with the company’s need to reinforce liquidity after reporting operating losses of $5.7 million in 2025 and going concern language in recent filings. This private placement brings $1.80 million in cash and converts $351,000 of related-party debt, with added upside if $2.69 million of warrants are exercised. Investors should weigh balance-sheet improvement against dilution and the company’s history of volatile reactions to operating updates.

Key Terms

private placement, warrants, securities purchase agreement, convertible bridge notes, +2 more

6 terms

private placement financial

"today announced the closing of a $2.15 million private placement of common stock and warrants"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

warrants financial

"private placement of common stock and warrants, and an additional $2.69 million if cash warrants are fully"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

securities purchase agreement financial

"The Company entered into a securities purchase agreement with a group of investors for the private"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

convertible bridge notes financial

"from the conversion of convertible bridge notes previously issued to certain directors who had made"

A convertible bridge note is a short-term loan a company takes to 'bridge' its funding until a larger financing round, with the loan automatically converting into shares instead of being repaid in cash. For investors, it matters because it behaves like an IOU that will become ownership at a future price (often at a reduced rate compared with new investors), affecting future share count, potential upside, and dilution risk.

NYSE American financial

"Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery"

NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.

Form 8-K regulatory

"set forth in the Company's Current Report on Form 8-K filed with the Securities and Exchange"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. Not financial advice.

Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board

ROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of a $2.15 million private placement of common stock and warrants, and an additional $2.69 million if cash warrants are fully exercised.

"Today we strengthened our balance sheet and positioned the company to capitalize on the increasing demand we are seeing across our product platforms," said Eric Hines, Chief Executive Officer of Milestone Scientific. "This financing allows us to build on our progress, scaling investment in sales, inventory and digital marketing, while maintaining our continued focus on cost discipline.”

"Importantly, participation from long-term investors and members of the Board, myself included, represents a strong endorsement of our technology and the direction of this Company.”

Transaction Summary

The Company entered into a securities purchase agreement with a group of investors for the private placement of 7,962,963 units at a price of $0.27 per unit. Each unit consists of one share of common stock and one corresponding cash warrant at 125% of unit purchase price. The Company sold $2.15 million of securities, comprised of approximately $1.80 million in cash and approximately $351,000 from the conversion of convertible bridge notes previously issued to certain directors who had made loans to the Company in 2025. No placement agent was used, and accordingly no placement or underwriting discounts, commissions, or other fees were paid.

As part of the cash raise, certain directors and officers participated in the offering on the same terms as all other investors, purchasing an aggregate of $150,000 of units for cash in addition to the bridge note conversions described above.

The Private Placement was conducted in accordance with applicable NYSE American rules and closed on April 20, 2026. Additional details regarding the transaction, including the securities purchase agreement and form of warrant, are set forth in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission. Investors are encouraged to review the 8-K for a complete description of the terms and conditions of the offering.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Any potential Category I designation is determined solely by the American Medical Association and is not guaranteed. Providers remain responsible for compliance with all applicable billing, coding, and regulatory requirements. Forward-looking case submission expectations, reimbursement targets, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity, and are subject to change based on clinical scheduling, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted reimbursement levels, or projected revenue levels will be achieved.

Contact:

HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

FAQ

How much did Milestone Scientific (MLSS) raise in the April 20, 2026 private placement?

The company raised $2.15 million in the closed offering, with $1.80 million raised in cash and $351,000 from note conversions, according to the company.

What securities did Milestone Scientific (MLSS) issue in the private placement?

Milestone issued 7,962,963 units, each unit including one common share and one cash warrant exercisable at 125% of the unit price, according to the company.

Will Milestone Scientific (MLSS) receive more cash from the warrants, and how much?

Yes, if all cash warrants are exercised, Milestone could receive an additional $2.69 million; warrant exercise is contingent and not guaranteed, according to the company.

Did Milestone Scientific (MLSS) executives participate in the April 2026 financing?

Yes, certain directors and officers, including the CEO and chairman, purchased an aggregate of $150,000 of units on the same terms, according to the company.

Were placement agents or commissions paid for Milestone Scientific's (MLSS) private placement?

No placement agent was used and no placement or underwriting discounts, commissions, or other fees were paid in connection with the offering, according to the company.